北京市金杜律师事务所 关于朗姿股份有限公司 2024 年第一次临时股东大会 之法律意见书 致：朗姿股份有限公司 北京市金杜律师事务所（以下简称本所）受朗姿股份有限公司（以下简称公司）委 托，根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人民共和国公司 法》（以下简称《公司法》）、中国证券监督管理委员会《上市公司股东大会规则（2022 年修订）》（以下简称《股东大会规则》）等中华人民共和国境内（以下简称中国境内， 为本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国台 湾地区）现行有效的法律、行政法规、规章及规范性文件和现行有效的《朗姿股份有限 公司章程》（以下简称《公司章程》）有关规定，指派律师出席了公司于 2024 年 3 月 26 日召开的 2024 年第一次临时股东大会（以下简称本次股东大会），并就本次股东 大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2022 年第一次临时股东大会审议通过的《公司章程》； 2. 公司于 2024 年 3 月 8 日在《证券时报》《上海证券报》及巨潮资讯网 （http: ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-015 朗姿股份有限公司 2024 年第一次临时股东大会决议公告 1、会议的召开情况 （1）召开时间： 现场会议召开时间：2024年3月26日下午14:00。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024年3月26日9:15-9:25，9:30-11:30和13:00-15:00。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为2024年3月 26日9:15至15:00期间的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、 会议召开和出席情况 （2）召开地点：北京市朝阳区西大望路27号大郊亭南街3号院1号楼（朗姿 大厦）16层会议室 （3）召开方式：现场投票和网络投票相结合的方式 （4）召集人：公司董事会 （5）主持人：董事长申东日先生 （6）本次会议的召集、召开符合《公司法》《深圳证券交易所股票上市规则》 及《公司章程》等有关规定，合法 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-014 朗姿股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）向兴业银行股份有限公司北京金融街支行（以下简称"兴业银行"） 申请最高授信额度 10,000 万元，公司控股股东、实际控制人申东日先生及其配 偶翁洁女士为公司提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 二、被担保人基本情况 朗姿股份有限公司 法定代表人：申东日 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 关于接受关联方担保的公告 3、债权人：兴业银行股份有限公司北京金融街支行 4、担保方式：连带责任保证 5、担保期限：主合同下债务履行期届满之日起三年 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：生产服装；销售服装、日用品、鞋帽箱包、五金、婴幼儿用品 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-013 特此公告。 朗姿股份有限公司董事会 单位：人民币万元 | 项目 | 2023 | 年年度 | | 2022 | 年年度 | | 增减率 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | | 100,889.08 | | | 91,213.62 | | | 10.61% | | 营业利润 | | 9,358.08 | | | 7,973.13 | | | 17.37% | | 利润总额 | | 9,312.84 | | | 8,075.73 | | | 15.32% | | 净利润 | | 6,870.12 | | | 5,407.94 | | | 27.04% | | | 2023 年 | 12 月 31 | 日 | 2022 年 | 12 月 31 | 日 | 增减率 | | | 资产总额 | | 123,244.83 | | | 116,414.00 | | | 5.87% | | 负债总额 | | 29,748.52 | | | 27,373.3 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-011 朗姿股份有限公司 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第十六次 会议通知于 2024 年 3 月 6 日以电话或其他口头通知方式发出，于 2024 年 3 月 7 日以通讯及现场会议方式召开。会议由董事长申东日先生主持，会议应出席董事 5 人，实际出席 5 人。公司监事及高级管理人员列席了本次会议。本次会议的召 开符合《中华人民共和国公司法》《朗姿股份有限公司章程》《朗姿股份有限公 司董事会议事规则》的有关规定，合法有效。 二、董事会会议审议情况 审议并通过了《关于召开公司 2024 年第一次临时股东大会的议案》 公司将于 2024 年 3 月 26 日召开 2024 年第一次临时股东大会，审议：《关 于现金收购郑州集美全部股权暨关联交易的议案》 具体内容请详见 2024 年 2 月 29 日公司刊登于《证券时报》《上海证券报》 及巨潮资讯网（www.cninfo.com.cn）的《关于现金收购郑州集美全部股权暨关联 交易的公告》《第五届董事会第十五次会议决议公告》。 关于召开 2024 年第一次临时股东大会的通 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-012 朗姿股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 朗姿股份有限公司（以下简称"公司"）于 2024 年 3 月 7 日召开第五届董事 会第十六次会议，审议通过了《关于召开公司 2024 年第一次临时股东大会的议 案》。本次股东大会审议的议案具体内容已披露在《证券时报》《上海证券报》 和巨潮资讯网（www.cninfo.com.cn）。 一、召开会议的基本情况 1、股东大会届次：2024年第一次临时股东大会。 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董事 会第十六次会议审议决定召开。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政 法规、部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： 现场会议召开时间：2024年3月26日下午14:00。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2024年3月26日9:15-9:25，9:30-11:30 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 25.84 CNY per share, indicating an expected performance that exceeds the market by more than 10% over the next 12 months [11][17][19]. Core Views - The acquisition of Zhengzhou Jimei is expected to enhance the company's medical beauty business and improve its financial condition. Zhengzhou Jimei, established in October 2020, has shown strong profitability potential, with projected net profits of 769.28 million CNY in 2023, recovering from a loss in 2022 [1][16]. - The company is on track for significant growth, with a forecasted net profit of 200-250 million CNY in 2023, representing a year-on-year increase of 835.99%-1069.99%. This growth is attributed to the recovery of both women's clothing and medical beauty businesses [1][2]. - The company has been actively acquiring medical beauty institutions, which is expected to enhance its scale and competitiveness in the industry. Recent acquisitions include stakes in Kunming Hancheng and Wuhan Wuzhou, all meeting their 2023 performance commitments [1][2]. Financial Summary - Revenue is projected to grow from 4,931 million CNY in 2023 to 6,374 million CNY by 2025, with growth rates of 27.1% and 13.9% respectively [2]. - The company's EBITDA is expected to increase from 595 million CNY in 2023 to 746 million CNY in 2025, reflecting a recovery in profitability [2]. - The forecasted earnings per share (EPS) for 2023-2025 are 0.53 CNY, 0.70 CNY, and 0.87 CNY respectively, indicating a positive trend in earnings [2][18].

Investment Rating - The investment rating for the company is "Accumulate (Maintain)" [12] Core Views - The company has demonstrated strong growth in its medical aesthetics business, with a significant increase in revenue and profitability. The acquisition of Zhengzhou Jimei Medical Institution is expected to enhance its national presence and operational scale [14][15] - The company is focusing on high-margin self-developed products in the medical aesthetics sector, which is expected to improve overall profitability [4] - Revenue projections for the company are optimistic, with expected revenues of 4.88 billion, 5.89 billion, and 6.63 billion yuan for 2023, 2024, and 2025 respectively, alongside substantial growth in net profit [15] Summary by Sections Medical Aesthetics Business - The non-surgical medical aesthetics revenue reached 743 million yuan in H1 2023, representing a year-on-year growth of 32.84%, accounting for 81.98% of total revenue [4] - The company has launched new products, including a high-end hyaluronic acid series and a self-developed regenerative material injection, enhancing its product portfolio and market positioning [4] Financial Performance - The company reported a net profit of 769 million yuan in 2023, recovering from a loss of 17.18 million yuan in 2022, indicating a significant turnaround [2][4] - Forecasted net profits for 2023, 2024, and 2025 are 246 million, 341 million, and 439 million yuan respectively, with growth rates of 1431.9%, 38.5%, and 28.7% [15] Acquisition Strategy - The company plans to acquire 100% of Zhengzhou Jimei Medical Institution for 155 million yuan, which is expected to further its national expansion strategy [14] - The acquisition is projected to contribute a minimum of 10.54 million yuan in net profit for 2024, with cumulative profits of at least 38.65 million yuan by 2026 [2][14]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][26]. Core Views - The company is expected to achieve a significant increase in net profit for 2023, with estimates ranging from 836% to 1070% growth, driven by the successful acquisition of a hospital [4]. - The acquisition of Zhengzhou Jimei, a specialized beauty hospital, is part of the company's ongoing expansion strategy, which is expected to enhance its medical beauty business and overall competitiveness [5][13]. - The company is projected to see steady growth across its three main business segments, with a dual growth strategy of "internal growth + external expansion" in the medical beauty sector [13][27]. Financial Summary - The company’s revenue is forecasted to grow from 5,111 million yuan in 2023 to 6,896 million yuan by 2025, reflecting a year-on-year growth rate of 31.8% in 2023, 18.1% in 2024, and 14.3% in 2025 [28]. - The net profit attributable to the parent company is expected to rise from 242 million yuan in 2023 to 410 million yuan in 2025, with a remarkable year-on-year increase of 1407.1% in 2023 [28]. - The company's gross margin is projected to remain stable, with estimates of 58.4% in 2023, 58.2% in 2024, and 58.0% in 2025 [28]. - Earnings per share (EPS) are expected to increase from 0.55 yuan in 2023 to 0.93 yuan in 2025, indicating a positive trend in profitability [28].

Investment Rating - The investment rating for the company is "Accumulate" [1] Core Views - The report highlights that the company is making further progress in its nationwide layout in the medical beauty sector, with the acquisition of Zhengzhou Jimei expected to enhance profitability and expand its market presence [9] - The medical beauty business is anticipated to continue its growth trajectory, supported by both external acquisitions and internal expansions, with projected net profits for 2023-2025 being CNY 2.37 billion, CNY 3.09 billion, and CNY 3.53 billion respectively [9] Financial Summary - Total revenue for the company is projected to grow from CNY 3,833 million in 2021 to CNY 6,416 million by 2025, with a compound annual growth rate (CAGR) of 12.3% [2] - The net profit attributable to the parent company is expected to rebound significantly from CNY 16 million in 2022 to CNY 353 million in 2025, reflecting a substantial growth rate of 14.3% [2] - The gross profit margin is forecasted to improve slightly from 56.7% in 2021 to 59.1% by 2025 [2] - The return on equity (ROE) is projected to increase from 0.6% in 2022 to 10.0% in 2025, indicating improved profitability [2] - The earnings per share (EPS) is expected to rise from CNY 0.04 in 2022 to CNY 0.80 in 2025, demonstrating strong earnings growth [2] Balance Sheet Overview - Total assets are expected to grow from CNY 7,110 million in 2022 to CNY 8,084 million by 2025, indicating a healthy asset base [3] - Current assets are projected to increase from CNY 2,032 million in 2022 to CNY 2,973 million in 2025, reflecting improved liquidity [3] - Total liabilities are anticipated to rise from CNY 3,492 million in 2022 to CNY 3,745 million by 2025, suggesting a manageable level of debt [3]